Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Gastric Cancer: early-phase trial registry
72 of 159 indexed Gastric Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #69 of 28,707 conditions by registered trial count.
159 US clinical trials · 72 currently recruiting · #69 of 28,707 conditions by registered trial count
Gastric Cancer: 159 US clinical trials tracked, 72 recruiting.
Gastric Cancer is the subject of 159 registered US clinical trials on ClinicalTrials.gov, 72 of them currently open to new participants. 17 are in Phase 3-4 (later-stage) and 118 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 11 of these trials.
Enrollment posture brief
Registry condition gastric-cancer
OPEN 72 | RECR 45% | LATE 17 | EARLY 118 | RANK #69 | SPON 11
Volume-matched condition peers
Nearest open-share peer: Non-Small Cell Lung Cancer (45% recruiting · 455 trials)
Gastric Cancer lists 72 open slots (45% of 159 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Gastric Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Gastric Cancer is recruiting above its size-band peers.
72 of 159 indexed trials (45.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Gastric Cancer trials is spread across many organizations.
AstraZeneca accounts for 11 of 159 trials (6.9%). 107 distinct sponsors appear on at least one study for this condition label.
-
Typical Gastric Cancer enrolment sits around 117 participants.
Median target enrolment is 117 among the 154 trials that report a genuine target (sentinel values excluded). 65 of those (42.2%) plan for fewer than 100 participants.
-
Gastric Cancer research is mostly interventional.
142 interventional and 17 observational studies make up this index (89.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
159 total, page 3 of 4
A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.
Amgen
NCT05322577
MAGE-A4ᶜ¹º³²T for Multi-Tumor
Adaptimmune
NCT03132922
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals
NCT05311618
First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
TORL Biotherapeutics
NCT05159440
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
Legend Biotech USA
NCT05539430
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio
NCT03228667
Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis
University of California, Irvine
NCT04762953
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Arcus Biosciences
NCT05891171
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03044613
Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2
Milton S. Hershey Medical Center
NCT06384417
Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers
University of Colorado, Denver
NCT05379972
A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers
Memorial Sloan Kettering Cancer Center
NCT06243757
Early Onset and Familial Gastric Cancer Registry
Memorial Sloan Kettering Cancer Center
NCT00582257
Stomach Cancer Exosome-based Detection
City of Hope Medical Center
NCT06342427
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
Hoffmann-La Roche
NCT01774786
A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma
Eli Lilly and Company
NCT01170663
Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer
Alliance for Clinical Trials in Oncology
NCT00052910
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Alliance for Clinical Trials in Oncology
NCT02349412
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
Bristol-Myers Squibb
NCT03662659
Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers
National Cancer Institute (NCI)
NCT04535414
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Dan Zandberg
NCT04157985
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Sanofi
NCT05104567
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01576666
Visceral Lymphatic Mapping Using Isosulfan Blue in Patients With Cancer of the Pancreas, Colon, Stomach, Small Intestine, or Gallbladder
Wake Forest University Health Sciences
NCT00489515
Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin
Dana-Farber Cancer Institute
NCT00831571
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Memorial Sloan Kettering Cancer Center
NCT00515411
Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
Eastern Cooperative Oncology Group
NCT00033657
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
Eli Lilly and Company
NCT02572687
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
Five Prime Therapeutics
NCT02318329
Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia
Mayo Clinic
NCT01471756
S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus
SWOG Cancer Research Network
NCT00012363
Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor
Northwestern University
NCT00711243
Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)
M.D. Anderson Cancer Center
NCT00525785
A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors
Halozyme Therapeutics
NCT02563548
Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer
Dana-Farber Cancer Institute
NCT00165464
Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy
Washington University School of Medicine
NCT05427214
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach
Jonsson Comprehensive Cancer Center
NCT00020761
A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer
ACT Biotech
NCT00952497
Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
Alliance for Clinical Trials in Oncology
NCT00040859
Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction
Alliance for Clinical Trials in Oncology
NCT00054457
Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer
NYU Langone Health
NCT00005049
Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer
Dana-Farber Cancer Institute
NCT00130689
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Jonsson Comprehensive Cancer Center
NCT00003748
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
NCT03652077
FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Yale University
NCT00673673
FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
NCT01913639
Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
Vanderbilt-Ingram Cancer Center
NCT00514020
Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer
NYU Langone Health
NCT00858338
Study of 5-Fluorouracil and Leucovorin and Intra-abdominal Floxuridine Chemoradiation in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma
University of Southern California
NCT00183911
Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors
Georgetown University
NCT00003125
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 69 |
| Phase 2 | 49 |
| Phase 3 | 13 |
| Phase 4 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Gastric Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Gastric Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Gastric Cancer page
159 registered trials, 72 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 72 Gastric Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Gastric Cancer trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gastric Cancer condition card totals 159 registered trials; most-linked intervention Paclitaxel; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.